{"id":"ar101-powder-provided-in-capsules","safety":{"commonSideEffects":[{"rate":"null","effect":"Gastrointestinal symptoms"},{"rate":"null","effect":"Anaphylaxis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AR101 works by gradually increasing tolerance to peanut protein through the ingestion of small, controlled amounts of peanut flour. This is achieved through a process called desensitization, where the body becomes less reactive to the presence of peanuts over time.","oneSentence":"AR101 is an oral immunotherapy for peanut allergy.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:29:00.401Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Peanut allergy"}]},"trialDetails":[{"nctId":"NCT03736447","phase":"PHASE3","title":"Peanut Oral Immunotherapy Study of Early Intervention for Desensitization","status":"COMPLETED","sponsor":"Aimmune Therapeutics, Inc.","startDate":"2018-12-27","conditions":"Peanut Allergy","enrollment":146},{"nctId":"NCT02635776","phase":"PHASE3","title":"Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)","status":"COMPLETED","sponsor":"Aimmune Therapeutics, Inc.","startDate":"2015-12-22","conditions":"Peanut Allergy","enrollment":555},{"nctId":"NCT02993107","phase":"PHASE3","title":"PALISADE Follow-on Study (ARC004)","status":"COMPLETED","sponsor":"Aimmune Therapeutics, Inc.","startDate":"2016-12-29","conditions":"Peanut Allergy","enrollment":388},{"nctId":"NCT01987817","phase":"PHASE2","title":"Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT","status":"COMPLETED","sponsor":"Aimmune Therapeutics, Inc.","startDate":"2014-02-06","conditions":"Peanut Allergy","enrollment":56},{"nctId":"NCT03126227","phase":"PHASE3","title":"Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)","status":"COMPLETED","sponsor":"Aimmune Therapeutics, Inc.","startDate":"2017-05-08","conditions":"Peanut Allergy","enrollment":506},{"nctId":"NCT03201003","phase":"PHASE3","title":"ARTEMIS Peanut Allergy In Children","status":"COMPLETED","sponsor":"Aimmune Therapeutics, Inc.","startDate":"2017-06-12","conditions":"Peanut Allergy","enrollment":175}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AR101 powder provided in capsules","genericName":"AR101 powder provided in capsules","companyName":"Aimmune Therapeutics, Inc.","companyId":"aimmune-therapeutics-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"AR101 is an oral immunotherapy for peanut allergy. Used for Peanut allergy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}